A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma

Recruiting in Palo Alto (17 mi)

+31 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Takeda

No Placebo Group

Breakthrough Therapy

Approved in 2 Jurisdictions

Trial Summary

What is the purpose of this trial?Participants with CD30-positive lympoma will be treated with brentuximab vedotin according to their clinic's standard practice. The main aim of this study is to collect information on any side effects from treatment with brentuximab vedotin. Other aims are to collect information on how brentuximab vedotin is used to treat these participants and the outcomes of these participants.

Eligibility Criteria

Inclusion Criteria

Undergoing treatment with brentuximab vedotin (of less than 3 months from initial treatment with brentuximab vedotin) or to be received with brentuximab vedotin.

CD30-positive lymphoma by INV (any CD30 expression)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Participants with CD30-positive LymphomaExperimental Treatment1 Intervention

All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.

Brentuximab Vedotin is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Adcetris for: